Search
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalA safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800] … [A34604] This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities.
Categories: Adrenergic alpha-1 Receptor AntagonistsNimesulide
go.drugbank.com/drugs/DB04743ApprovedWithdrawnNimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and...
Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical UsePenicillamine
go.drugbank.com/drugs/DB00859ApprovedInvestigationalPenicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no a...
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755] … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220318,L16408] Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalIt was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.
Ordopidine
go.drugbank.com/drugs/DB05196InvestigationalACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalThe FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with … Imlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader.
Categories: Estrogen Receptor Antagonists, Selective Estrogen Receptor DegradersHalazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawnHalazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects. It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United S...
Inosine pranobex
go.drugbank.com/drugs/DB13156ApprovedInosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.
Categories: Antiinfectives for Systemic Use